{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Monotherapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Combination Therapy (receiving AVD or NAVD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Number of participants who died in Cohort D within 100 days after last dose of study therapy.","groups":[{"description":"Four doses of nivolumab flat dose 240 mg IV were administered every 2 weeks (monotherapy phase), followed by 12 doses of the combination of AVD (adriamycin/ doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) chemotherapy and nivolumab flat dose 240 mg IV for 6 cycles (combination phase).","id":"OG000","title":"Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Cohort D participants treated in the monotherapy and combination therapy phases.","reportingStatus":"POSTED","timeFrame":"From first dose of the considered therapy phase to 100 days after last dose of study therapy phase (or up to first dose of combination if any when considering the monotherapy period) (an average of 10 months up to a maximum of 13 months)","title":"Number of Participants Who Died in Cohort D","type":"SECONDARY","unitOfMeasure":"Participants"}